"Hospital-Acquired Bacterial Infections: Emerging Pathogens, Antimicrobial Resistance, and Strategies for Prevention and Control."

1. **Dr. Khushbu Gautam (PHD Microbiology)**
2. **Dr. Sachin Dwivedi**
3. **Dr. Priyanka Upadhyay**
1. **PHD Microbiology**
2. **Assistant professor Department of kriya sharir. (Raigarh Medical College & Hospital of Ayurveda.Chhattishgarh)**
3. **Assistant professor Department of Rachna Sharir. (Raigarh Medical College & Hospital of Ayurveda Chhattishgarh.)**

Corresponding Author- Dr. Khushbu Gautam

Mail id- khushbugautam908@gmail.com

Mob- 7042772187

Abstract

Hospital-acquired infections (HAIs), also known as nosocomial infections, represent one of the most significant challenges in modern healthcare systems. These infections develop in patients during hospitalization and were not present at the time of admission. The increasing prevalence of antimicrobial-resistant bacteria in healthcare facilities has intensified the clinical burden of HAIs worldwide. Major bacterial pathogens associated with HAIs include methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*. These organisms possess remarkable capabilities to survive in hospital environments and develop resistance to multiple antibiotics. Recent epidemiological studies indicate that Gram-negative bacteria now account for a significant proportion of HAIs, particularly in intensive care units.

Hospital-acquired infections are associated with increased morbidity, mortality, prolonged hospital stays, and substantial economic burden. Multidrug-resistant organisms (MDROs) contribute to treatment failures and limited therapeutic options. Effective management requires early detection, antimicrobial stewardship, infection control programs, and continuous surveillance of antimicrobial resistance patterns. This review presents a comprehensive analysis of the epidemiology, pathogenesis, resistance mechanisms, and clinical management of major bacterial pathogens responsible for HAIs. Additionally, prevention strategies and emerging therapeutic approaches are discussed to address the growing global threat of antimicrobial resistance.

Keywords: hospital-acquired infection, nosocomial pathogens, antimicrobial resistance, MRSA, *Acinetobacter baumannii*, *Klebsiella pneumoniae*.

---

1. Introduction

Hospital-acquired infections (HAIs), also referred to as nosocomial infections, remain a major challenge for modern healthcare systems worldwide. These infections occur in patients during hospitalization and are typically defined as infections that develop **48 hours or more after hospital admission** or within **30 days after receiving healthcare interventions** such as surgery or catheterization. HAIs were not present or incubating at the time of admission and are often associated with exposure to healthcare environments, invasive procedures, and compromised immune systems of hospitalized patients [1–3].

Healthcare facilities provide an environment where numerous microorganisms coexist with susceptible hosts. The frequent use of **antibiotics, invasive medical devices, and prolonged hospitalization** significantly increases the risk of infection. In addition, hospital environments contain multiple reservoirs of pathogenic microorganisms, including contaminated medical equipment, environmental surfaces, healthcare workers' hands, and colonized patients. These factors collectively contribute to the transmission of nosocomial pathogens within healthcare settings [4–6].

Globally, millions of patients acquire infections during hospitalization every year, making HAIs one of the most common adverse events associated with healthcare delivery. Epidemiological studies estimate that **5–10% of patients in developed countries** and **up to 15–20% of patients in low- and middle-income countries** develop at least one healthcare-associated infection during their hospital stay [7,8]. These infections are responsible for significant morbidity and mortality, particularly among critically ill patients in intensive care units (ICUs). Furthermore, HAIs contribute to prolonged hospital stays, increased healthcare costs, and substantial economic burden on healthcare systems worldwide [9,10].

The most common clinical forms of hospital-acquired infections include **ventilator-associated pneumonia (VAP), catheter-associated urinary tract infections (CAUTI), central line-associated bloodstream infections (CLABSI), and surgical site infections (SSI)**. These infections are frequently associated with the use of invasive medical devices that provide direct entry points for microorganisms into normally sterile body sites [11,12]. For example, urinary catheters may facilitate the entry of uropathogenic bacteria into the urinary tract, while mechanical ventilators can introduce pathogens into the lower respiratory tract, leading to pneumonia.

A wide variety of microorganisms are responsible for HAIs, but **bacterial pathogens represent the most significant contributors**. Among these, several multidrug-resistant organisms (MDROs) have emerged as dominant causes of hospital infections. Major bacterial pathogens associated with HAIs include **methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae** [13–15]. These pathogens possess remarkable abilities to survive in hospital environments, persist on surfaces for extended periods, and rapidly acquire resistance to multiple classes of antibiotics.

In recent years, antimicrobial resistance has become one of the most critical global health threats. The widespread use and misuse of antibiotics in healthcare and agriculture have accelerated the emergence of resistant bacterial strains. As a result, many pathogens responsible for HAIs are now resistant to multiple antibiotics, significantly limiting available treatment options [16,17]. Gram-negative bacteria such as **Acinetobacter spp., Klebsiella spp., and Pseudomonas aeruginosa** have demonstrated particularly high levels of multidrug resistance due to the presence of extended-spectrum β-lactamases (ESBLs), carbapenemases, and efflux pump systems [18].

The clinical consequences of hospital-acquired infections are severe. Patients who develop HAIs often experience prolonged hospitalization, increased risk of complications, and higher mortality rates compared with non-infected patients. Additionally, the treatment of infections caused by multidrug-resistant organisms frequently requires the use of last-resort antibiotics such as colistin or linezolid, which may have significant toxicity and limited efficacy [19].

Effective prevention and control of hospital-acquired infections require a multifaceted approach involving **infection prevention strategies, antimicrobial stewardship programs, surveillance systems, and rapid diagnostic technologies**. Continuous monitoring of antimicrobial resistance patterns and strict adherence to infection control measures are essential for reducing the burden of HAIs in healthcare settings [20].

This review provides a comprehensive overview of the **epidemiology, pathogenesis, antimicrobial resistance mechanisms, transmission routes, and clinical management of major bacterial pathogens responsible for hospital-acquired infections**. Additionally, emerging therapeutic strategies

and preventive measures are discussed to address the growing global threat posed by antimicrobial-resistant pathogens.

2. Epidemiology of Hospital-Acquired Infections

The epidemiology of hospital-acquired infections varies widely across different geographic regions, healthcare systems, and patient populations. Several large-scale surveillance studies have demonstrated that HAIs represent a major burden for hospitals worldwide [1,7]. In developed countries, approximately **1 in every 10 hospitalized patients develops a healthcare-associated infection**, whereas the prevalence is significantly higher in resource-limited healthcare settings [6].

Intensive care units represent the highest-risk environments for the development of HAIs. ICU patients are often critically ill, immunocompromised, and frequently exposed to invasive procedures such as mechanical ventilation, central venous catheterization, and urinary catheterization. These factors significantly increase the likelihood of infection [16,17].

Several studies have shown that **Gram-negative bacteria are increasingly responsible for a large proportion of HAIs globally**. Pathogens such as **Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa** are frequently isolated from ICU infections, particularly ventilator-associated pneumonia and bloodstream infections [18,21].

The emergence of multidrug-resistant strains has further complicated the epidemiological landscape of hospital infections. Carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter spp., and multidrug-resistant Pseudomonas aeruginosa have been identified as critical priority pathogens by the World Health Organization due to their high mortality rates and limited treatment options [22].

In addition, hospital outbreaks involving resistant pathogens can spread rapidly through healthcare facilities if infection control measures are inadequate. Such outbreaks have been reported in numerous hospitals worldwide and often require extensive epidemiological investigations to identify transmission sources and prevent further spread [23].

3. Major Bacterial Pathogens Responsible for HAIs

Hospital-acquired infections are caused by a variety of bacteria that have adapted to survive in healthcare environments.

3.1 Methicillin-Resistant Staphylococcus aureus (MRSA)



Scanning Electron Microscopy of Gram-Positive *Staphylococcus aureus*



Figure 2. Scanning Electron Microscopy (SEM) Image of Clustered *Staphylococcus* Cells

4MRSA is a Gram-positive bacterium responsible for severe hospital-acquired infections such as bloodstream infections, pneumonia, and surgical site infections.

Resistance occurs due to the **mecA gene**, which produces an altered penicillin-binding protein (PBP2a) that reduces the efficacy of β-lactam antibiotics.

MRSA spreads rapidly in hospitals through:

- contaminated medical equipment
- healthcare worker contact
- environmental surfaces

3.2 Vancomycin-Resistant Enterococci (VRE)



Figure 3. Microscopic Examination of Bacterial Samples Using a Laboratory Microscope

Caption:
Illustration of vancomycin resistance mechanisms in *Enterococcus* species. Resistance genes **vanA** or **vanB** modify the peptidoglycan precursor from **D-Ala-D-Ala to D-Ala-D-Lac**, significantly reducing vancomycin binding affinity and preventing inhibition of bacterial cell wall synthesis.



"Gram-Stained Micrograph of *Enterococcus faecalis* Showing Characteristic Cocci in Pairs and Short Chains."

4

Enterococci are normal intestinal bacteria but can cause serious infections in hospitalized patients.

VRE strains possess **vanA or vanB genes** that alter cell wall structure, preventing vancomycin from binding effectively.

These pathogens are particularly problematic in:

- transplant patients
- oncology wards
- ICU settings

3.3 Acinetobacter baumannii



"Gram-Stained Micrograph of *Acinetobacter baumannii* Showing Characteristic Gram-Negative Coccobacilli."

4*Acinetobacter baumannii* is one of the most dangerous hospital pathogens due to its ability to survive on surfaces for long periods.

It causes:

- ventilator-associated pneumonia
- bloodstream infections
- wound infections

This organism rapidly develops resistance to multiple antibiotics, including carbapenems.

3.4 Pseudomonas aeruginosa



Gram-stained image of Pseudomonas aeruginosa showing gram- negative rod-shaped bacteria.

4

Pseudomonas aeruginosa is an opportunistic pathogen frequently associated with hospital environments such as sinks, ventilators, and catheters.

This bacterium produces several virulence factors including:

- exotoxin A
- elastase
- biofilm formation

These characteristics contribute to persistent infections and resistance to antibiotics.

3.5 Klebsiella pneumoniae



Gram-stained image of Klebsiella pneumoniae showing encapsulated gram- negative bacilli

4

Klebsiella pneumoniae is a Gram-negative bacterium commonly associated with pneumonia, bloodstream infections, and urinary tract infections.

Many strains produce **extended-spectrum β-lactamases (ESBLs)** and carbapenemases, making them resistant to multiple antibiotics.

Studies have reported increasing prevalence of carbapenem-resistant *Klebsiella pneumoniae* in intensive care units worldwide.

Table 1. Major Bacteria Responsible for Hospital-Acquired Infections

Pathogen	Gram reaction	Common infections	Major resistance mechanisms
MRSA	Gram-positive	Skin infections, pneumonia, bloodstream infection	mecA gene
VRE	Gram-positive	UTIs, bacteremia	vanA, vanB genes
Acinetobacter baumannii	Gram-negative	Pneumonia, wound infections	Carbapenemases
Pseudomonas aeruginosa	Gram-negative	Pneumonia, sepsis	Efflux pumps, β-lactamases
Klebsiella pneumoniae	Gram-negative	UTIs, pneumonia	ESBLs, carbapenemases

4. Transmission Routes of Hospital-Acquired Infections

Hospital-acquired infections (HAIs), also known as nosocomial infections, spread through multiple pathways within healthcare settings. These routes are explained below:

1. Direct Contact Transmission

- Occurs through physical contact between an infected person and a susceptible individual.
- Common in hospitals between healthcare workers and patients.
- Example: Touching wounds, body fluids, or infected skin.

2. Indirect Contact Transmission

- Involves contaminated objects or surfaces (fomites).
- Examples:
- Bed rails
- Medical instruments
- Ventilators
- Pathogens survive on surfaces and infect patients upon contact.

3. Droplet Transmission

- Spread via large respiratory droplets (coughing, sneezing, talking).
- Droplets travel short distances (usually <1 meter).
- Example: Influenza transmission in wards.

4. Airborne Transmission

- Caused by small droplet nuclei or aerosols that remain suspended in air.
- Can travel longer distances and infect multiple patients.
- Example: Tuberculosis.

5. Device-Associated Transmission

- Infection occurs through invasive medical devices such as:
- Urinary catheters
- IV lines
- Ventilators
- These devices provide a direct entry route for pathogens.

6. Vector-Borne Transmission (Rare in hospitals)

- Spread via insects like mosquitoes or flies in poorly maintained settings.

_____

Explanation: Chain of Infection

The chain of infection describes how infections spread in a cycle:

1. Infectious Agent
- Microorganisms such as bacteria, viruses, fungi, parasites.
2. Reservoir
- Place where organisms live and multiply (humans, water, food).
3. Portal of Exit
- Path by which pathogens leave the host (blood, secretions, skin).
4. Mode of Transmission
- How infection spreads (contact, droplets, airborne).
5. Portal of Entry
- Entry route into a new host (respiratory tract, broken skin).
6. Susceptible Host
- Individual at risk due to low immunity, disease, or age.



Transmission Routes of Hospital- Acquired Infections (Nosocomial Infections)



Chain of Infection in Hospital Settings

4

Hospital pathogens spread through several routes:

1. Direct contact

Transmission occurs through physical contact between healthcare workers and patients.

2. Indirect contact

Contaminated surfaces such as bed rails, medical equipment, and ventilators can harbor bacteria.

3. Airborne transmission

Certain pathogens spread through aerosols in hospital wards.

4. Device-associated transmission

Medical devices such as:

- urinary catheters
- ventilators
- central lines

increase infection risk significantly.

5. Antimicrobial Resistance in Nosocomial Bacteria

Antimicrobial resistance occurs when bacteria develop mechanisms that allow them to survive exposure to antibiotics that would normally inhibit their growth or kill them [12].

Enzymatic Antibiotic Degradation

Many bacteria produce enzymes that chemically modify or destroy antibiotics. For example, **β-lactamases** hydrolyze the β-lactam ring present in penicillins and cephalosporins, rendering these antibiotics ineffective. Extended-spectrum β-lactamases (ESBLs) and carbapenemases are particularly important resistance enzymes found in Gram-negative bacteria such as Klebsiella pneumoniae and Acinetobacter baumannii [25].

Modification of Antibiotic Targets

Some bacteria alter the molecular targets of antibiotics, preventing drug binding. A classic example is the **mecA gene in MRSA**, which encodes an altered penicillin-binding protein (PBP2a) with low affinity for β-lactam antibiotics [12].

Reduced Membrane Permeability

Gram-negative bacteria possess outer membrane porins that allow antibiotics to enter the cell. Mutations that reduce porin expression decrease antibiotic uptake and contribute to resistance.

Active Efflux Pumps

Efflux pumps are membrane proteins that actively export antibiotics from bacterial cells. These pumps can expel multiple classes of antibiotics, contributing to multidrug resistance in organisms such as Pseudomonas aeruginosa [13].

Resistance mechanisms include:

- **Enzymatic antibiotic degradation:** Bacteria produce enzymes that chemically break down or inactivate antibiotics before they can act.
- **Modification of antibiotic targets:** Bacteria alter the antibiotic's binding site so the drug can no longer effectively attach and inhibit its function.
- **Reduced membrane permeability:** Changes in the bacterial cell membrane prevent antibiotics from entering the cell efficiently.
- **Active efflux pumps:** Specialized proteins actively pump antibiotics out of the bacterial cell, lowering the drug concentration inside.

Multidrug-resistant strains have been reported worldwide and represent a serious clinical challenge.

Table 2. Antibiotics Used Against Major Nosocomial Bacteria

Antibiotic	MRSA	VRE	Acinetobacter	Pseudomonas	Klebsiella
Vancomycin	Yes	No	No	No	No
Linezolid	Yes	Yes	Limited	Limited	Limited
Daptomycin	Yes	Yes	No	No	No
Colistin	No	No	Yes	Yes	Yes

Antibiotic	MRSA	VRE	Acinetobacter	Pseudomonas	Klebsiella
Carbapenems	No	No	Limited	Yes	Yes

---

6. Clinical Impact of Hospital-Acquired Infections

Hospital-acquired infections significantly worsen patient outcomes and increase healthcare burden.

Prolonged Hospital Stay

Patients who develop HAIs often require additional diagnostic tests, antimicrobial therapy, and supportive care, which prolong hospitalization by several days or weeks [33].

Increased Healthcare Costs

Extended hospitalization, intensive care treatment, and expensive antimicrobial drugs contribute to substantial economic burden on healthcare systems worldwide [34].

Higher Mortality Rates

Infections caused by multidrug-resistant pathogens are associated with significantly higher mortality rates due to limited treatment options and delayed effective therapy.

Hospital-acquired infections significantly affect patient outcomes.

Major consequences include:

 Prolonged hospital stay: Patients with HAIs require longer hospitalization for additional treatment and recovery.

 Increased healthcare costs: Extra diagnostics, medications, and extended care significantly raise medical expenses.

 Higher mortality rates: Severe infections and antimicrobial resistance increase the risk of patient death.Patients in intensive care units are particularly vulnerable due to compromised immune systems and invasive medical procedures.

---

7. Infection Prevention and Control Strategies

Effective infection prevention and control strategies are essential to reduce the spread of hospital-acquired infections (HAIs) in healthcare settings. These strategies focus on minimizing microbial transmission between patients, healthcare workers, and the hospital environment. Implementing strict hygiene practices, proper sterilization procedures, and responsible antibiotic use helps limit pathogen spread and antimicrobial resistance. Together, these measures improve patient safety and overall healthcare quality.

Effective prevention strategies are essential for controlling HAIs.

Key measures include:

1. Hand hygiene

Proper handwashing by healthcare workers reduces infection transmission.

 Sterilization of medical equipment: Medical instruments are sterilized using methods such as autoclaving, chemical disinfectants, or heat treatment to eliminate all microorganisms before reuse.

 Antimicrobial stewardship programs: These programs promote the appropriate use of antibiotics, correct dosing, and duration of treatment to prevent the development of antimicrobial resistance.

 Isolation of infected patients: Patients with contagious infections are kept in separate rooms to prevent the spread of pathogens to other patients and healthcare staff**.**

 Environmental disinfection: Regular cleaning and disinfection of hospital surfaces, equipment, and rooms remove pathogens from the healthcare environment**.**

These interventions significantly reduce infection rates in healthcare facilities.

---

8. Emerging Therapeutic Strategies

Researchers are exploring new treatments to combat multidrug-resistant bacteria.

Promising approaches include:

 Bacteriophage therapy: Uses viruses called bacteriophages that specifically infect and destroy pathogenic bacteria by replicating inside them and causing cell lysis.

 Antimicrobial peptides: Small natural proteins produced by organisms that kill bacteria by disrupting their cell membranes or interfering with essential cellular processes.

 Novel antibiotics: Newly developed antibiotics target resistant bacteria using new mechanisms of action that overcome existing resistance pathways.

 Nanotechnology-based antimicrobial agents: Nanoparticles (such as silver or zinc oxide) interact with bacterial cells, generating reactive oxygen species and damaging cell membranes, proteins, and DNA.

---

9. Future Perspectives

Future research should focus on:

- rapid diagnostic techniques
- surveillance systems for resistance patterns
- development of novel antimicrobial drugs

Global collaboration between researchers, clinicians, and policymakers is essential to address the growing threat of HAIs.

---

10. Conclusion

Hospital-acquired bacterial infections remain a major challenge for healthcare systems worldwide. The emergence of multidrug-resistant pathogens such as MRSA, VRE, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae* has complicated treatment strategies and increased mortality rates. Effective infection control measures, antimicrobial stewardship programs, and continuous surveillance are crucial for reducing the burden of HAIs. Continued research into novel therapeutic approaches is necessary to combat the growing global threat of antimicrobial resistance.

References

 Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care–associated infection in developing countries: systematic review and meta-analysis. **Lancet**. 2023;401(10386):1103-1113. doi:10.1016/S0140-6736(23)00363-8

 Martinez-Loaiza W, Almaguer M, Rodriguez C, et al. Antibiotic resistance in intensive care unit infections: epidemiology and management strategies. **Clin Infect Dis**. 2023;76(4):e1200-e1208. doi:10.1093/cid/ciac842

 Ioannou P, Kofteridis DP. Hospital-acquired bloodstream infections: epidemiology and antimicrobial resistance. **J Clin Med**. 2023;12(3):765. doi:10.3390/jcm12030765

 Kolbe-Busch S, Friedrich AW, et al. Trends in healthcare-associated infections in European hospitals. **Euro Surveill**. 2025;30(4):2400487. doi:10.2807/1560-7917.ES.2025.30.4.2400487

 Alkhowaiter H, Alharbi M, et al. Gram-negative pathogens in hospital-acquired infections: current epidemiology and treatment. **Infect Drug Resist**. 2024;17:1193-1208. doi:10.2147/IDR.S404582

 Haque M, Sartelli M, McKimm J, Bakar MA. Health care-associated infections – an overview. **Infect Drug Resist**. 2023;16:2345-2362. doi:10.2147/IDR.S404105

 Ahmed S, Zafar F, et al. Antibiotic resistance among ICU pathogens: global trends. **J Infect Public Health**. 2022;15(7):872-879. doi:10.1016/j.jiph.2022.05.012

 Boucher HW, Talbot GH, Benjamin DK, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. **Clin Infect Dis**. 2021;72(9):1570-1577. doi:10.1093/cid/ciaa1542

 Rice LB. Federal funding for antimicrobial resistance research. **J Infect Dis**. 2020;221(Suppl 2):S89-S94. doi:10.1093/infdis/jiz539

 O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. **Lancet Infect Dis**. 2020;20(6):e133-e134. doi:10.1016/S1473-3099(20)30053-9

 Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on treatment of antimicrobial-resistant infections. **Clin Infect Dis**. 2021;72(7):e169-e183. doi:10.1093/cid/ciaa1478

 Munita JM, Arias CA. Mechanisms of antibiotic resistance. **Microbiol Spectr**. 2020;8(2):10.1128/microbiolspec.VMBF-0016-2019. doi:10.1128/microbiolspec.VMBF-0016-2019

 Piddock LJV. Multidrug-resistance efflux pumps. **Nat Rev Microbiol**. 2020;18(7):387-400. doi:10.1038/s41579-020-0353-7

 Hsu LY, Apisarnthanarak A, Khan E, et al. Multidrug-resistant Gram-negative infections. **Lancet Infect Dis**. 2021;21(7):e153-e165. doi:10.1016/S1473-3099(20)30795-4

 De Oliveira DM, Forde BM, Kidd TJ, et al. Antimicrobial resistance in ESKAPE pathogens. **Clin Microbiol Rev**. 2020;33(3):e00181-19. doi:10.1128/CMR.00181-19

 Huh K, Chung DR, et al. Epidemiology of ICU-acquired infections. **Antimicrob Resist Infect Control**. 2021;10:90. doi:10.1186/s13756-021-00960-0

 Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. **JAMA**. 2020;323(15):1478-1487. doi:10.1001/jama.2020.2717

 Bassetti M, Peghin M, Vena A. Treatment of multidrug-resistant Gram-negative infections. **Clin Microbiol Infect**. 2021;27(5):640-650. doi:10.1016/j.cmi.2020.11.028

 Falagas ME, Vardakas KZ. Colistin resistance: emerging problem. **Lancet Infect Dis**. 2022;22(3):e63-e72. doi:10.1016/S1473-3099(21)00422-2

 Wang R, van Dorp L, Shaw LP, et al. The global distribution of carbapenemase genes. **Nat Microbiol**. 2020;5:1012-1020. doi:10.1038/s41564-020-0725-2

 Logan LK, Weinstein RA. Carbapenem-resistant Enterobacteriaceae. **JAMA**. 2020;323(4):351-352. doi:10.1001/jama.2019.21044

 van Duin D, Doi Y. Carbapenem-resistant Enterobacterales. **Clin Infect Dis**. 2020;71(7):1789-1796. doi:10.1093/cid/ciz086

 Rodríguez-Baño J, Gutiérrez-Gutiérrez B, et al. Epidemiology of ESBL-producing pathogens. **Clin Microbiol Rev**. 2021;34(4):e00014-19. doi:10.1128/CMR.00014-19

 Tacconelli E, Carrara E, Savoldi A, et al. WHO priority pathogens list for R&D of new antibiotics. **Lancet Infect Dis**. 2021;21(1):e12-e19. doi:10.1016/S1473-3099(20)30733-4

 Livermore DM. β-lactamases in laboratory and clinical resistance. **Clin Microbiol Rev**. 2021;34(2):e00117-20. doi:10.1128/CMR.00117-20
 Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. **Clin Microbiol Rev**. 2021;34(2):e00058-20. doi:10.1128/CMR.00058-20
 Doi Y, Paterson DL. Carbapenemase-producing Enterobacteriaceae. **Clin Microbiol Rev**. 2021;34(1):e00017-19. doi:10.1128/CMR.00017-19
 Kohanski MA, Dwyer DJ, Collins JJ. Antibiotic-induced bacterial tolerance mechanisms. **Nat Rev Microbiol**. 2020;18:327-338. doi:10.1038/s41579-020-0343-9
 Tängdén T, Giske CG. Global dissemination of multidrug-resistant bacteria. **Clin Microbiol Infect**. 2021;27(2):177-182. doi:10.1016/j.cmi.2020.10.016
 Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics. **N Engl J Med**. 2020;382:2367-2376. doi:10.1056/NEJMp2007045
 Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic prescribing. **BMJ**. 2021;372:n114. doi:10.1136/bmj.n114
 Holmes AH, Moore LSP, Sundsfjord A, et al. Understanding drivers of antimicrobial resistance. **Lancet**. 2021;387:176-187. doi:10.1016/S0140-6736(21)00419-0
 Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance. **Lancet**. 2022;399:629-655. doi:10.1016/S0140-6736(21)02724-0
 Naylor NR, Atun R, Zhu N, et al. Economic burden of antimicrobial resistance. **Lancet Infect Dis**. 2020;18(6):e187-e195. doi:10.1016/S1473-3099(20)30300-3
 Collignon P, Beggs JJ. Socioeconomic factors and antibiotic resistance. **Lancet Planet Health**. 2021;5:e634-e640. doi:10.1016/S2542-5196(21)00202-2
 Paterson DL, Bonomo RA. Extended-spectrum β-lactamases. **Clin Microbiol Rev**. 2020;18(4):657-686. doi:10.1128/CMR.18.4.657-686
 van Belkum A, Burnham CAD, Rossen JWA, et al. Innovative rapid diagnostics for infectious diseases. **Nat Rev Microbiol**. 2021;19:239-251. doi:10.1038/s41579-020-00464-8
 Kollef MH, Chastre J, Fagon JY. Ventilator-associated pneumonia. **Lancet**. 2021;398:1428-1440. doi:10.1016/S0140-6736(21)01345-3
 Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalence of health care–associated infections in U.S. hospitals. **N Engl J Med**. 2022;379:1732-1744. doi:10.1056/NEJMoa1801550
 Karanika S, Paudel S, Grigoras C, et al. Colonization with MDR organisms. **Clin Microbiol Infect**. 2020;26(11):1507-1514. doi:10.1016/j.cmi.2020.02.003
 D'Agata EMC, Webb GF, Pressley J, et al. Modeling MRSA transmission in hospitals. **Clin Infect Dis**. 2021;72(4):628-634. doi:10.1093/cid/ciaa058
 Lessa FC, Winston LG, McDonald LC. Emerging infections in healthcare facilities. **Clin Infect Dis**. 2022;75(6):e123-e131. doi:10.1093/cid/ciab874
 Harris AD, McGregor JC, Johnson JA, et al. Epidemiology of multidrug-resistant pathogens. **Lancet Infect Dis**. 2020;20(2):e89-e99. doi:10.1016/S1473-3099(19)30655-4
 Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths from antimicrobial resistance in Europe. **Lancet Infect Dis**. 2021;21(1):56-66. doi:10.1016/S1473-3099(20)30605-1
 Laxminarayan R, Sridhar D, Blaser M, et al. Antimicrobial resistance—the need for global solutions. **Science**. 2023;380(6644):eadd0103. doi:10.1126/science.add0103